Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-hodgkin lymphoma Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Lymphoma, Non-Hodgkin

abstract

  • R-CBorP is a safe and effective regimen in patients with relapsed/refractory indolent and MCLs. Most toxicities were grade 1 or 2, and a promising response rate was seen in this phase I study.

publication date

  • April 15, 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5639472

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-10-1498

PubMed ID

  • 21346146

Additional Document Info

start page

  • 2493

end page

  • 501

volume

  • 17

number

  • 8